Advertisement

Advertisement
Lung Cancer

Patients With Interstitial Lung Disease Face Elevated Lung Cancer Risk, Study Finds

A large prospective cohort study conducted by Ye and Kang et al and published in JAMA Network Open found that, after adjusting for familial and other cancer-related factors, interstitial lung disease (ILD) was associated with an increased risk of developing most histologic subtypes of lung cancer.

 

Issues in Oncology

Realizing the Full Potential of Patient Engagement in Clinical Research

Nothing about us without us is a centuries-old value that is a cornerstone of meaningful patient engagement in clinical research. Such engagement has not been automatic and is still largely absent in geriatric oncology research, where older patients traditionally have been excluded from clinical trials, and consideration has not been given to the inclusion of similar patients as partners in the research. There’s been progress in the past couple of decades, but there is still a long way to go to realize the full potential of patient engagement in clinical research: to make it standard research practice.

 

Breast Cancer
Survivorship

Intense Resistance Training for Breast Cancer Survivors With Lymphedema Risk

Resistance training can provide many benefits, including increased muscle mass; decreased adipose tissue; and improved metabolism, bone density, strength, and mobility. However, data are limited on the association between resistance training and the development or exacerbation of lymphedema, a common and potentially debilitating consequence of breast cancer treatment. In a recent study reported in JAMA Network Open, Shamsesfandabadi et al examined the association between resistance training and lymphedema among breast cancer survivors.

 


Advertisement
Colorectal Cancer

Association of Type 2 Diabetes With Colorectal Cancer Risk and Survival by Tumor Immunity Status

In a German population–based, matched case-control study reported in the Journal of Clinical Oncology, Wankhede et al found that type 2 diabetes (T2D) may be associated with colorectal cancer (CRC) risk and survival according to tumor immunity status.

 

American Cancer Society Names New CEO

The American Cancer Society (ACS) and its advocacy affiliate the American Cancer Society Cancer Action Network (ACS CAN) have announced Shane Jacobson as their Chief Executive Officer, effective August 12, 2025. He steps into the role following Wayne A.I. Frederick, MD, MBA, FACS, who has served as interim Chief Executive Officer of both organizations since November 2024.

 

Advertisement
Advertisement




More Top Stories


Hematologic Malignancies

Rami S. Komrokji, MD, on Myelodysplastic Neoplasms: Classifying Risks Among Subsets of Disease

Pancreatic Cancer

Surviving Pancreatic Cancer

I’ve been blessed to have remained healthy for most of my life. In fact, I can’t remember ever spending a night in the hospital until I was diagnosed with pancreatic cancer, at age 86, in the summer of 2024. And even then, the symptoms that drove me to seek care in the emergency room of my local...

Advertisement

The Inflation Reduction Act and Ibrutinib

Charles L. Bennett, MD, PhD, MPP Steven T. Rosen, MD Gerard F. Anderson, PhD In August 2024, the Centers for Medicare & Medicaid Services (CMS) announced a negotiated price for the Bruton’s tyrosine kinase inhibitor ibrutinib that is 38% lower than the manufacturer’s list price....

Paolo Corradini, MD, on PMBCL and DLBCL: Comparing Outcomes With Axicabtagene Ciloleucel

Breast Cancer

Immunotherapy Combination: A Potential New Standard in Triple-Negative Breast Cancer

In the phase III ASCENT-04/KEYNOTE-D19 trial, the combination of the TROP2-directed antibody-drug conjugate sacituzumab govitecan-hziy plus the PD-1 inhibitor pembrolizumab in previously untreated patients with PD-L1–positive advanced triple-negative breast cancer significantly reduced the risk of...

Breast Cancer

Does Menopausal Hormone Therapy Increase the Risk of Death in Women With BRCA-Mutated Breast Cancer?

The risk of death does not appear to increase with the use of menopausal hormone therapy in women with early-onset, BRCA-mutated breast cancer who began hormone supplementation after diagnosis, based on preliminary data presented during the 2025 ASCO Annual Meeting.1 “Management of early surgical...

Update to ASCO Living Guideline for NSCLC Without Driver Alterations Includes First Comparison of Immunotherapy Options

ASCO has issued a new update to its living guideline regarding therapy for stage IV non–small cell lung cancer (NSCLC) without driver alterations, based on results of three studies published recently.1 The update (the first since a previous version in February 2025) includes discussion of...

Hematologic Malignancies
Leukemia

Nigel Russell, MD, on Acute Myeloid Leukemia: New Findings on FLAG-Ida and Gemtuzumab Ozogamicin

Lung Cancer

Does Exposure to Wildfire-Dominated, Inhalable, Fine Particulate Matter Impact Survival in NSCLC?

Higher ambient exposure to a type of inhalable, fine particulate matter was found to be associated with an increased risk of cancer-related death for patients who were diagnosed with non–small cell lung cancer (NSCLC) while living in California—a state where wildfires are becoming more prevalent,...

Advertisement

Studies on EGFR Mutations and NRG1 Fusions Included in ASCO NSCLC Living Guideline Update

ASCO has issued a new update to its living guideline on treatment of stage IV non–small cell lung cancer (NSCLC) with driver alterations based on two recent studies.1 The update, which amends the most recent version published in February 2025, includes a discussion of osimertinib therapy options in ...

ASCO Post X Feed
Social Media Hub by Everwall